The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids.
The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids.
复制标题
DOI：
10.1161/circresaha.115.306807
复制
发表时间：
2015-10-09
影响因子：
20.1
通讯作者：
Zhernakova A
中科院分区：
文献类型：
--
作者：
Fu J;Bonder MJ;Cenit MC;Tigchelaar EF;Maatman A;Dekens JA;Brandsma E;Marczynska J;Imhann F;Weersma RK;Franke L;Poon TW;Xavier RJ;Gevers D;Hofker MH;Wijmenga C;Zhernakova A
文本中提供了补充数字内容。有证据表明，肠道微生物群与心血管疾病的发展有关，宿主与微生物之间的相互作用调节免疫和代谢途径。然而，大规模的人类研究并没有确凿的证据表明微生物群与心血管疾病代谢危险因素之间存在关联。特别是，没有强有力的证据表明心血管疾病与血脂水平异常之间存在关联。鉴定肠道细菌分类群，其比例与体重指数和脂质水平相关，并确定脂质变异是否可以通过与年龄、性别和宿主遗传学相关的微生物群来解释。我们研究了来自 LifeLines-DEEP 人群队列的 893 名受试者。在校正年龄和性别后，我们确定了 34 个与体重指数和血脂相关的细菌分类群；大多数都是新奇的联想。交叉验证分析显示，微生物群可以解释 4.5% 的体重指数差异、6% 的甘油三酯差异和 4% 的高密度脂蛋白差异，且与年龄、性别和遗传风险因素无关。包含肠道微生物组的新型风险模型解释了 ≤25.9% 的高密度脂蛋白方差，显着优于没有微生物组的风险模型。引人注目的是，微生物组对低密度脂蛋白或总胆固醇几乎没有影响。我们的研究表明，肠道微生物组可能在体重指数和血脂水平的变化中发挥重要作用，与年龄、性别和宿主遗传无关。我们的研究结果支持通过改变肠道微生物组来控制体重、甘油三酯和高密度脂蛋白的疗法的潜力。
Supplemental Digital Content is available in the text. Evidence suggests that the gut microbiome is involved in the development of cardiovascular disease, with the host–microbe interaction regulating immune and metabolic pathways. However, there was no firm evidence for associations between microbiota and metabolic risk factors for cardiovascular disease from large-scale studies in humans. In particular, there was no strong evidence for association between cardiovascular disease and aberrant blood lipid levels. To identify intestinal bacteria taxa, whose proportions correlate with body mass index and lipid levels, and to determine whether lipid variance can be explained by microbiota relative to age, sex, and host genetics. We studied 893 subjects from the LifeLines-DEEP population cohort. After correcting for age and sex, we identified 34 bacterial taxa associated with body mass index and blood lipids; most are novel associations. Cross-validation analysis revealed that microbiota explain 4.5% of the variance in body mass index, 6% in triglycerides, and 4% in high-density lipoproteins, independent of age, sex, and genetic risk factors. A novel risk model, including the gut microbiome explained ≤25.9% of high-density lipoprotein variance, significantly outperforming the risk model without microbiome. Strikingly, the microbiome had little effect on low-density lipoproteins or total cholesterol. Our studies suggest that the gut microbiome may play an important role in the variation in body mass index and blood lipid levels, independent of age, sex, and host genetics. Our findings support the potential of therapies altering the gut microbiome to control body mass, triglycerides, and high-density lipoproteins.